Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renaparin for Improvement of Kidney Graft Function in Deceased-Donor Transplant Recipients
2022-501389-23-00Phase 2Withdrawn
- Sponsor
- Corline Biomedical
- Start
- Jan 2023
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of Renaparin in end-stage kidney disease (ESKD) and chronic kidney disease (CKD) (2 arms), sponsored by Corline Biomedical. Primary endpoint: Estimated glomerular filtration rate (eGFR) at Month 3. Planned start Jan 2023; status: withdrawn.
02
Drugs
Renaparin
03
Conditions
end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-501389-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501389-23-00.